Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| plasmacytoid dendritic cell | 4 studies | 21% ± 4% |
Insufficient scRNA-seq data for expression of EIF4EBP3 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| ovary | 100% | 948.06 | 180 / 180 | 99% | 10.95 | 427 / 430 |
| prostate | 100% | 1508.86 | 245 / 245 | 98% | 5.21 | 494 / 502 |
| kidney | 100% | 1129.94 | 89 / 89 | 97% | 4.39 | 873 / 901 |
| thymus | 100% | 1272.28 | 653 / 653 | 95% | 3.35 | 575 / 605 |
| brain | 97% | 432.04 | 2569 / 2642 | 92% | 2.68 | 651 / 705 |
| intestine | 100% | 1190.36 | 966 / 966 | 88% | 5.36 | 464 / 527 |
| stomach | 100% | 1343.96 | 359 / 359 | 87% | 4.66 | 248 / 286 |
| pancreas | 100% | 884.87 | 328 / 328 | 87% | 2.53 | 154 / 178 |
| liver | 100% | 905.65 | 226 / 226 | 84% | 2.59 | 343 / 406 |
| breast | 100% | 1443.83 | 459 / 459 | 84% | 2.71 | 936 / 1118 |
| esophagus | 100% | 1039.69 | 1445 / 1445 | 77% | 1.64 | 141 / 183 |
| skin | 99% | 1205.10 | 1794 / 1809 | 77% | 2.38 | 363 / 472 |
| uterus | 100% | 814.65 | 170 / 170 | 70% | 1.73 | 322 / 459 |
| lung | 100% | 1022.74 | 577 / 578 | 65% | 1.44 | 747 / 1155 |
| bladder | 100% | 1061.67 | 21 / 21 | 63% | 3.02 | 319 / 504 |
| adrenal gland | 100% | 1961.94 | 258 / 258 | 60% | 1.37 | 137 / 230 |
| adipose | 100% | 1291.00 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 100% | 14.92 | 80 / 80 |
| muscle | 100% | 1994.79 | 803 / 803 | 0% | 0 | 0 / 0 |
| spleen | 100% | 1319.78 | 241 / 241 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 715.94 | 1333 / 1335 | 0% | 0 | 0 / 0 |
| heart | 98% | 691.26 | 848 / 861 | 0% | 0 | 0 / 0 |
| peripheral blood | 97% | 658.37 | 902 / 929 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 73% | 1.83 | 33 / 45 |
| lymph node | 0% | 0 | 0 / 0 | 72% | 1.67 | 21 / 29 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0045947 | Biological process | negative regulation of translational initiation |
| GO_0016281 | Cellular component | eukaryotic translation initiation factor 4F complex |
| GO_0016020 | Cellular component | membrane |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005634 | Cellular component | nucleus |
| GO_0030371 | Molecular function | translation repressor activity |
| GO_0005515 | Molecular function | protein binding |
| GO_0008190 | Molecular function | eukaryotic initiation factor 4E binding |
| Gene name | EIF4EBP3 |
| Protein name | Eukaryotic translation initiation factor 4E-binding protein 3 (4E-BP3) (eIF4E-binding protein 3) |
| Synonyms | |
| Description | FUNCTION: Repressor of translation initiation that regulates EIF4E activity by preventing its assembly into the eIF4F complex: the hypophosphorylated form competes with EIF4G1/EIF4G3 and strongly binds to EIF4E, leading to repression of translation. In contrast, the hyperphosphorylated form dissociates from EIF4E, allowing interaction between EIF4G1/EIF4G3 and EIF4E, leading to initiation of translation (By similarity). Inhibits EIF4E-mediated mRNA nuclear export . . |
| Accessions | O60516 ENST00000310331.3 |